MX363437B - Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors. - Google Patents

Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors.

Info

Publication number
MX363437B
MX363437B MX2015007562A MX2015007562A MX363437B MX 363437 B MX363437 B MX 363437B MX 2015007562 A MX2015007562 A MX 2015007562A MX 2015007562 A MX2015007562 A MX 2015007562A MX 363437 B MX363437 B MX 363437B
Authority
MX
Mexico
Prior art keywords
pyrimido
diones
quinoline
nonsense mutation
mutation suppressors
Prior art date
Application number
MX2015007562A
Other languages
Spanish (es)
Other versions
MX2015007562A (en
Inventor
Jacoby Edgar
Reinhardt Juergen
Schmiedeberg Niko
Spanka Carsten
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX363437(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2015007562A publication Critical patent/MX2015007562A/en
Publication of MX363437B publication Critical patent/MX363437B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Inorganic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to compound of the formula (I); or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
MX2015007562A 2012-12-13 2013-12-12 Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors. MX363437B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261736748P 2012-12-13 2012-12-13
PCT/IB2013/060859 WO2014091446A1 (en) 2012-12-13 2013-12-12 Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors

Publications (2)

Publication Number Publication Date
MX2015007562A MX2015007562A (en) 2015-10-14
MX363437B true MX363437B (en) 2019-03-22

Family

ID=50030361

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007562A MX363437B (en) 2012-12-13 2013-12-12 Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors.

Country Status (24)

Country Link
US (2) US9649314B2 (en)
EP (1) EP2931282B1 (en)
JP (1) JP6076498B2 (en)
KR (1) KR101760586B1 (en)
CN (2) CN104837490B (en)
AP (1) AP2015008441A0 (en)
AU (1) AU2013358591B2 (en)
BR (1) BR112015013535A2 (en)
CA (1) CA2890692A1 (en)
CL (1) CL2015001610A1 (en)
CR (1) CR20150314A (en)
CU (1) CU20150061A7 (en)
EA (1) EA028673B1 (en)
ES (1) ES2709034T3 (en)
HK (1) HK1209637A1 (en)
IL (1) IL239244A0 (en)
IN (1) IN2015DN03998A (en)
MA (1) MA38157A1 (en)
MX (1) MX363437B (en)
PE (1) PE20151062A1 (en)
PH (1) PH12015501216A1 (en)
SG (1) SG11201503684WA (en)
TN (1) TN2015000262A1 (en)
WO (1) WO2014091446A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2931282B1 (en) 2012-12-13 2018-10-31 Novartis AG Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors
MY178379A (en) * 2014-06-03 2020-10-09 Novartis Ag Naphthyridinedione derivatives as suppressors of non-sense mutations
EP3152207B1 (en) 2014-06-03 2019-05-08 Novartis AG Pyridopyrimidinedione derivatives as suppressors of non-sens mutations
EP3152208B1 (en) * 2014-06-03 2019-05-08 Novartis AG Pyrimido[4,5-b]quinoline-4,5(3h,10h)-dione derivatives as suppressors of non-sens mutations
WO2017181193A2 (en) * 2016-04-15 2017-10-19 The Uab Research Foundation Methods and compounds for stimulating read-through of premature termination codons
WO2019173437A1 (en) * 2018-03-06 2019-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Positive allosteric modulators of dopamine 1 receptor and method of use thereof
WO2019225625A1 (en) * 2018-05-23 2019-11-28 京都薬品工業株式会社 Readthrough inducer and pharmaceutical use thereof
WO2022053651A2 (en) 2020-09-10 2022-03-17 Precirix N.V. Antibody fragment against fap
WO2022152821A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2884170B2 (en) 1989-08-24 1999-04-19 株式会社フジモト・ブラザーズ Anticancer agent containing 5-deazaflavin compound as active ingredient
US5908930A (en) * 1995-03-15 1999-06-01 Pfizer Inc. 5,10-dihydropyrimdo 4,5-b!quinolin-4(1H)-one tyrosine kinase inhibitors
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
WO2004006906A2 (en) 2002-07-15 2004-01-22 Combinatorx, Incorporated Methods for the treatment of neoplasms
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
ES2624610T3 (en) 2003-04-11 2017-07-17 Ptc Therapeutics, Inc. Compounds of 1,2,4-oxadiazole benzoic acid and their use for nonsense suppression and disease treatment
ES2689539T3 (en) 2006-04-03 2018-11-14 Technion Research & Development Foundation Ltd. Novel aminoglycosides and their uses in the treatment of genetic disorders
TW200819454A (en) 2006-08-23 2008-05-01 Neurogen Corp Haloalkyl-substituted pyrimidinone derivatives
JP2011507910A (en) * 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター Methods for changing the lifetime of eukaryotes
EP2422817A1 (en) 2010-07-29 2012-02-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Flavin-nucleic acid ligand conjugates
WO2012016930A1 (en) * 2010-08-05 2012-02-09 Universite De Droit Et Sante De Lille Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
EP2931282B1 (en) 2012-12-13 2018-10-31 Novartis AG Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors

Also Published As

Publication number Publication date
ES2709034T3 (en) 2019-04-12
US20170266189A1 (en) 2017-09-21
PH12015501216A1 (en) 2015-08-17
US9649314B2 (en) 2017-05-16
EA028673B1 (en) 2017-12-29
JP6076498B2 (en) 2017-02-08
CU20150061A7 (en) 2015-12-23
AU2013358591B2 (en) 2016-08-25
AU2013358591A1 (en) 2015-05-28
US20150335646A1 (en) 2015-11-26
CN104837490B (en) 2017-10-03
CL2015001610A1 (en) 2015-08-07
SG11201503684WA (en) 2015-06-29
IL239244A0 (en) 2015-07-30
AP2015008441A0 (en) 2015-05-31
KR20150092306A (en) 2015-08-12
CA2890692A1 (en) 2014-06-19
EA201591105A1 (en) 2015-10-30
HK1209637A1 (en) 2016-04-08
IN2015DN03998A (en) 2015-10-02
WO2014091446A1 (en) 2014-06-19
EP2931282B1 (en) 2018-10-31
CN104837490A (en) 2015-08-12
MX2015007562A (en) 2015-10-14
EP2931282A1 (en) 2015-10-21
KR101760586B1 (en) 2017-07-21
BR112015013535A2 (en) 2017-07-11
CR20150314A (en) 2015-08-10
CN107569487A (en) 2018-01-12
JP2016503003A (en) 2016-02-01
MA38157A1 (en) 2016-12-30
TN2015000262A1 (en) 2016-10-03
PE20151062A1 (en) 2015-08-05

Similar Documents

Publication Publication Date Title
TN2015000262A1 (en) Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors
MY191628A (en) Novel triazolo[4,5-d]pyrimidine derivatives
PH12017500755A1 (en) 2 substituted cephem compounds
SA515360469B1 (en) Heterocyclic compounds for inhibiting glutaminase and their methods of use
MX2015014298A (en) Dihydropyrido pyrimidine compounds as autotaxin inhibitors.
IN2014DN09434A (en)
UA117590C2 (en) Solar protection glazing
MX2014012477A (en) Pyrrolopyrazone inhibitors of tankyrase.
MX2014014832A (en) Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase.
MX2016009251A (en) 7-oxo-1,6-diazabicyclo[3.2.1 ]octane derivatives and their use as antibacterial agents.
MX340574B (en) Imidazo pyrazines.
MX2016012997A (en) (5,6-dihydro)pyrimido[4,5-e]indolizines.
IN2014DN10449A (en)
SA517381678B1 (en) Dihydropyrimidin-2-One Compounds and Medical Use Thereof
PH12018501709A1 (en) Naphthridinedione derivatives
PH12017500342A1 (en) 7 - (morpholinyl) -2- (n-piperazinyl) methyl thieno [2,3-c] pyridine derivatives as anticancer drugs
MX2014015345A (en) Pyranopyridone inhibitors of tankyrase.
PH12015500399A1 (en) Azaindolines
MX2015017446A (en) New macrocyclic amidinourea derivatives, methods of preparation and uses thereof as chitinase inhibitors.
MX2013009456A (en) Vinyl -aryl - sulfones for use in peritoneal carcinomatosis.
TN2013000231A1 (en) Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer